Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events and renal outcomes in patients with diabetes mellitus (DM). This meta-analysis aimed to provide a thorough evaluation regarding the efficacy and safety of SGLT2 inhibitors. Data search of MEDLINE/PubMed, Embase, and Cochrane Library databases and ClinicalTrials.com from inception through November 26, 2020. We included randomized trials, SGLT2 inhibitors compared with placebo, patients with or without diabetes at recruitment, and reporting the incidence of cardiovascular or renal outcomes. Two authors extracted pertinent data into predefined data collection tables. Ten trials were included (71,553 patients). The mean age was 64.7 ± 8.4 years, with 65.1% male. Follow-up durations range 9–50 months. Inhibition of SGLT2 resulted in lower composite outcome of heart failure (HF) hospitalization or cardiovascular death (RR 0.76, 95% CI 0.73–0.81, P < 0.01) and lower risk of renal outcomes (RR 0.68, 95% CI 0.60–0.77, P < 0.01). Furthermore, SGLT2 inhibitors were associated with lower major adverse cardiovascular events (MACEs), HF hospitalization, cardiovascular mortality, all-cause mortality, myocardial infarction, and serious adverse events, compared with placebo (P < 0.05). Sensitivity analyses revealed lower MACE events also in patients with HF, and a lower HF hospitalization and cardiovascular mortality in non-diabetic patients (P < 0.05). While the amputation risk was comparable between the two groups, the risk of diabetic ketoacidosis was higher in the SGLT2 inhibitor group. Inhibition of SGLT2 in patients with DM and prevalent ASCVD reduces the risk of HF hospitalization, cardiovascular mortality, all-cause mortality, MACE, and renal outcomes without increasing the risk of serious adverse events or amputation.
Similar content being viewed by others
References
Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321. https://doi.org/10.1016/j.diabres.2011.10.029
Roger VL, Go AS, Lloyd-Jones DM et al (2011) Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 123:e18–e209. https://doi.org/10.1161/CIR.0b013e3182009701
Ahmad FS, Ning H, Rich JD et al (2016) Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart failure 4:911–919. https://doi.org/10.1016/j.jchf.2016.08.001
Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Fail 23:628–651. https://doi.org/10.1016/j.cardfail.2017.04.014
Ogurtsova K, da Rocha Fernandes JD, Huang Y et al (2017) IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024
American Diabetic Association (2020) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 43:S98–S110. https://doi.org/10.2337/dc20-S009
Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89. https://doi.org/10.1177/1479164114561992
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744
Packer M (2020) SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508–511. https://doi.org/10.2337/dci19-0074
Wiviott SD, Raz I, Bonaca MP et al (2019) dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435. https://doi.org/10.1056/NEJMoa2004967
Bhatt DL, Szarek M, Pitt B et al (2020) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2030186
Bhatt DL, Szarek M, Steg PG et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2030183
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34. https://doi.org/10.1016/j.jclinepi.2009.06.006
Thorlund K, Devereaux PJ, Wetterslev J et al (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286. https://doi.org/10.1093/ije/dyn179
Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2024816
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2022190
Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:e563–e595. https://doi.org/10.1161/CIR.0000000000000677
Das SR, Everett BM, Birtcher KK et al (2018) 2018 acc expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Dec. J Am Coll Cardiol 72:3200–3223. https://doi.org/10.1016/j.jacc.2018.09.020
American Diabetic Association (2018) 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 41:S86–S104. https://doi.org/10.2337/dc18-S009
Packer M, Anker SD, Butler J et al (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2:1025–1029. https://doi.org/10.1001/jamacardio.2017.2275
Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108–2117. https://doi.org/10.1007/s00125-018-4670-7
Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44:457–464. https://doi.org/10.1016/j.diabet.2018.09.005
Author information
Authors and Affiliations
Contributions
All the included authors contributed significantly to accomplish this study. Dr. Barbarawi had full access to all data in the study and take responsibility for the integrity and accuracy of the data analysis. Concept and design: Barbarawi, Chen. Acquisition, analysis, or interpretation of data: Barbarawi, O. Barbarawi, Alabdouh, Lakshman, Chen. Drafting of the manuscript: Barbarawi, Chen. Critical revision of the manuscript for important intellectual content: Barbarawi, O. Barbarawi, Alabdouh, Lakshman, Chen. Statistical analysis: Barbarawi, Alabdouh, O. Barbarawi. Administrative, technical, or material support: Barbarawi, Alabdouh, O. Barbarawi. Supervision: Barbarawi, Chen.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Barbarawi, M., Al-abdouh, A., Barbarawi, O. et al. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev 27, 951–960 (2022). https://doi.org/10.1007/s10741-021-10083-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-021-10083-z